{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:59:02Z","timestamp":1785416342982,"version":"3.56.0"},"reference-count":59,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute of Health","award":["R01CA222959"],"award-info":[{"award-number":["R01CA222959"]}]},{"name":"National Institute of Health","award":["R01AI176670"],"award-info":[{"award-number":["R01AI176670"]}]},{"name":"National Institute of Health","award":["R21CA292295"],"award-info":[{"award-number":["R21CA292295"]}]},{"award":["R01CA222959"],"award-info":[{"award-number":["R01CA222959"]}],"id":[{"id":"https:\/\/ror.org\/02hssy432","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01AI176670"],"award-info":[{"award-number":["R01AI176670"]}],"id":[{"id":"https:\/\/ror.org\/02hssy432","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R21CA292295"],"award-info":[{"award-number":["R21CA292295"]}],"id":[{"id":"https:\/\/ror.org\/02hssy432","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006784","name":"Golfers Against Cancer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006784","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/05tte0y64","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001797","name":"PhRMA Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/029sjzg14","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000928","name":"Robert A. Welch Foundation","doi-asserted-by":"publisher","award":["BE0023"],"award-info":[{"award-number":["BE0023"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JFB"],"abstract":"<jats:p>Although immunotherapy has shown great promise in treating various types of cancer, advanced tumors are often refractory due to a highly immunosuppressive tumor microenvironment (TME). We previously engineered a cancer therapeutic vaccine platform, \u00b5GCVax, by co-loading tumor antigen peptides, STING and TLR9 agonists into porous silicon microparticles. While effective in models with lower disease burden, its efficacy against advanced colorectal cancer (CRC) was less promising due to the accumulation of myeloid-derived suppressor cells (MDSCs) in TMEs. In this study, we investigated whether \u00b5GCVax-based immunotherapy in advanced CRCs could be potentiated via regulating MDSCs to reprogram the TME. In an advanced CT26 murine CRC model, we assessed \u00b5GCVax in combination with oxaliplatin, a standard CRC chemotherapeutic with established immunomodulatory effects. We demonstrated that oxaliplatin was preferentially taken up by monocytic MDSCs (M-MDSCs) and effectively reduced their abundance in the bone marrow, blood, spleen, and tumor. Relief of this immunosuppressive TME increased intratumoral infiltration of antigen-specific CD8+ T cells. Ultimately, the combination of oxaliplatin with \u00b5GCVax induced robust regression of established CRC tumors. These findings highlight that oxaliplatin synergizes with \u00b5GCVax by overcoming MDSC-mediated immunosuppression and enhancing antitumor immunity, representing a promising chemo-immunotherapy strategy for advanced CRC.<\/jats:p>","DOI":"10.3390\/jfb17040185","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:20:16Z","timestamp":1775816416000},"page":"185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Potentiation of a Porous Silicon Therapeutic Vaccine in Colorectal Cancer via Oxaliplatin-Mediated Regulation of Myeloid-Driven Immunosuppression"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5211-4278","authenticated-orcid":false,"given":"Yongbin","family":"Liu","sequence":"first","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busra","family":"Akay Hacan","sequence":"additional","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0334-1890","authenticated-orcid":false,"given":"Junjun","family":"Zheng","sequence":"additional","affiliation":[{"name":"Center for Immunotherapy and Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX 77030, USA"},{"name":"Immunomonitoring Core, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1551-7531","authenticated-orcid":false,"given":"Xueying","family":"Ge","sequence":"additional","affiliation":[{"name":"School of Engineering Medicine\/ENMED, Texas A&M University and Houston Methodist Hospital, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Yu","sequence":"additional","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitian","family":"Xu","sequence":"additional","affiliation":[{"name":"Center for Immunotherapy and Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX 77030, USA"},{"name":"Immunomonitoring Core, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Shao","sequence":"additional","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa","family":"Shen","sequence":"additional","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderic I.","family":"Pettigrew","sequence":"additional","affiliation":[{"name":"School of Engineering Medicine\/ENMED, Texas A&M University and Houston Methodist Hospital, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-4221","authenticated-orcid":false,"given":"Ping-Ying","family":"Pan","sequence":"additional","affiliation":[{"name":"Center for Immunotherapy and Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Hsia","family":"Chen","sequence":"additional","affiliation":[{"name":"Center for Immunotherapy and Neal Cancer Center, Houston Methodist Academic Institute, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-4352","authenticated-orcid":false,"given":"Junhua","family":"Mai","sequence":"additional","affiliation":[{"name":"Center for BioNanoengineering, Houston Methodist Academic Institute, Houston, TX 77030, USA"},{"name":"Immunomonitoring Core, Houston Methodist Neal Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wu, S., Zhang, Y., Lin, Z., and Wei, M. (2025). Global burden of colorectal cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15138-0"},{"key":"ref_2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/annonc\/mdt157","article-title":"Current status of screening for colorectal cancer","volume":"24","author":"Garborg","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_4","first-page":"233","article-title":"Colorectal cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-20-1803","article-title":"Multicenter Phase I\/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503\/SCOOP Trial)","volume":"26","author":"Kawazoe","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-024-04790-w","article-title":"Advancements in immunotherapy for colorectal cancer treatment: A comprehensive review of strategies, challenges, and future prospective","volume":"40","author":"Kaviyarasan","year":"2024","journal-title":"Int. J. Color. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1038\/s41591-025-03876-4","article-title":"Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: Phase 1 AMPLIFY-201 trial final results","volume":"31","author":"Wainberg","year":"2025","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"10021","DOI":"10.3389\/ebm.2024.10021","article-title":"A phase 1 trial of human telomerase reverse transcriptase (hTERT) vaccination combined with therapeutic strategies to control immune-suppressor mechanisms","volume":"249","author":"Zareian","year":"2024","journal-title":"Exp. Biol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: The phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.semcancer.2018.04.003","article-title":"Checkpoints and beyond\u2014Immunotherapy in colorectal cancer","volume":"55","author":"Gutting","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104775","DOI":"10.1016\/j.critrevonc.2025.104775","article-title":"Immunotherapy in microsatellite-stable colorectal cancer: Strategies to overcome resistance","volume":"212","author":"Chen","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"LBA13","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA13","article-title":"A randomized phase 2 study of an individualized neoantigen-targeting immunotherapy in patients with newly diagnosed metastatic microsatellite stable colorectal cancer (MSS-CRC)","volume":"43","author":"Hecht","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2100166","DOI":"10.1002\/advs.202100166","article-title":"Synergistic Activation of Antitumor Immunity by a Particulate Therapeutic Vaccine","volume":"8","author":"Mai","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trsl.2022.06.004","article-title":"A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine","volume":"249","author":"Adam","year":"2022","journal-title":"Transl. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1158\/0008-5472.CAN-17-3415","article-title":"Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy","volume":"78","author":"Bauer","year":"2018","journal-title":"Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","article-title":"Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy","volume":"24","author":"He","year":"2025","journal-title":"Mol. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.immuni.2016.01.014","article-title":"CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation","volume":"44","author":"Kumar","year":"2016","journal-title":"Immunity"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","article-title":"Myeloid-derived suppressor cells: An emerging target for anticancer immunotherapy","volume":"21","author":"Wu","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3892\/ijo.2024.5673","article-title":"Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in colorectal cancer (Review)","volume":"65","author":"Zeng","year":"2024","journal-title":"Int. J. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41423-019-0306-1","article-title":"Myeloid immunosuppression and immune checkpoints in the tumor microenvironment","volume":"17","author":"Nakamura","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"122835","DOI":"10.1016\/j.biomaterials.2024.122835","article-title":"Novel platinum therapeutics induce rapid cancer cell death through triggering intracellular ROS storm","volume":"314","author":"Liu","year":"2025","journal-title":"Biomaterials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.2010.31.1936","article-title":"Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104\u2014A randomized trial of the German AIO CRC study group","volume":"29","author":"Moosmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1038\/s41598-023-29363-9","article-title":"Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model","volume":"13","author":"Alimohammadi","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gut.2010.211722","article-title":"Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice","volume":"60","author":"Alzuguren","year":"2011","journal-title":"Gut"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.canlet.2019.10.020","article-title":"TLR 7\/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages","volume":"469","author":"Liu","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/cam4.1878","article-title":"Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-kappaB signaling","volume":"8","author":"Kim","year":"2019","journal-title":"Cancer Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1935557","DOI":"10.1080\/2162402X.2021.1935557","article-title":"Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients","volume":"10","author":"Mulder","year":"2021","journal-title":"Oncoimmunology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/IJN.S341394","article-title":"Antitumor Immunity from Abdominal Flap-Embedded Therapeutic Cancer Vaccine","volume":"17","author":"Liu","year":"2022","journal-title":"Int. J. Nanomed."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.4049\/jimmunol.2100719","article-title":"The Sympathetic Nervous System Modulates Cancer Vaccine Activity through Monocyte-Derived Cells","volume":"207","author":"Hinkle","year":"2021","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cyto.a.24501","article-title":"PeacoQC: Peak-based selection of high quality cytometry data","volume":"101","author":"Emmaneel","year":"2022","journal-title":"Cytometry A"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e70231","DOI":"10.1002\/mco2.70231","article-title":"Myeloid-Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations","volume":"6","author":"Hu","year":"2025","journal-title":"MedComm"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"kyad008","DOI":"10.1093\/discim\/kyad008","article-title":"Behind the monocyte\u2019s mystique: Uncovering their developmental trajectories and fates","volume":"2","author":"Teh","year":"2023","journal-title":"Discov. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/nri1668","article-title":"Regulation of immune responses by L-arginine metabolism","volume":"5","author":"Bronte","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1158\/0008-5472.CAN-16-3199","article-title":"CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer","volume":"77","author":"Wang","year":"2017","journal-title":"Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41416-018-0333-1","article-title":"Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression","volume":"120","author":"Groth","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s41568-025-00872-1","article-title":"The immune microenvironment of colorectal cancer","volume":"25","author":"Kennel","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2020.06.030","article-title":"Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer","volume":"137","author":"Ammari","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e010791","DOI":"10.1136\/jitc-2024-010791","article-title":"Oxaliplatin, ATR inhibitor and anti-PD-1 antibody combination therapy controls colon carcinoma growth, induces local and systemic changes in the immune compartment, and protects against tumor rechallenge in mice","volume":"13","author":"Fauvre","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/gutjnl-2018-317257","article-title":"Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma","volume":"69","author":"Liu","year":"2020","journal-title":"Gut"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.immuni.2014.10.020","article-title":"Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways","volume":"41","author":"Haverkamp","year":"2014","journal-title":"Immunity"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1021\/jacsau.5c00217","article-title":"LA-ICP-TOFMS Imaging Reveals Significant Influence of Cancer Cell Resistance on Oxaliplatin Compartmentalization in the Tumor Microenvironment","volume":"5","author":"Schaier","year":"2025","journal-title":"JACS Au"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1172\/JCI84427","article-title":"The impact of hypoxia on tumor-associated macrophages","volume":"126","author":"Henze","year":"2016","journal-title":"J. Clin. Invest."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e178146","DOI":"10.1172\/jci.insight.178146","article-title":"Sustained inhibition of CSF1R signaling augments antitumor immunity through inhibiting tumor-associated macrophages","volume":"10","author":"Sato","year":"2025","journal-title":"JCI Insight"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/imm.13959","article-title":"PI3Kgamma in Tumour Inflammation: Bridging Immune Response and Cancer Progression-A Mini-Review","volume":"176","author":"Ghebremedhin","year":"2025","journal-title":"Immunology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11442","DOI":"10.18632\/oncotarget.2556","article-title":"Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils","volume":"5","author":"Seignez","year":"2014","journal-title":"Oncotarget"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: The immunogenic effects of platinum-based chemotherapeutics","volume":"20","author":"Hato","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1038\/s41416-023-02392-x","article-title":"Advancing translational research for colorectal immuno-oncology","volume":"129","author":"Thomas","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1158\/1078-0432.CCR-21-0529","article-title":"Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer","volume":"27","author":"Marisa","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"12369","DOI":"10.18632\/oncotarget.3682","article-title":"Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer","volume":"6","author":"Dufait","year":"2015","journal-title":"Oncotarget"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2326-6066.CIR-22-0116","article-title":"VISTA Targeting of T-cell Quiescence and Myeloid Suppression Overcomes Adaptive Resistance","volume":"11","author":"Schaafsma","year":"2023","journal-title":"Cancer Immunol. Res."}],"container-title":["Journal of Functional Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-4983\/17\/4\/185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T08:43:21Z","timestamp":1776156201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-4983\/17\/4\/185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":59,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["jfb17040185"],"URL":"https:\/\/doi.org\/10.3390\/jfb17040185","relation":{},"ISSN":["2079-4983"],"issn-type":[{"value":"2079-4983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]}}}